NanoViricides, a development stage company, has reported effectiveness of an anti-influenza drug candidate, under FluCide program, when given orally. According to the information received from the contract laboratory that performed the ...
Ambit Biosciences and Teva Pharmaceutical Industries have announced the FDA clearance of CEP-32496, a novel BRAF (V600E) kinase inhibitor. The preclinical findings also demonstrate that CEP-32496 possesses potent and sustained anti-tumor ...
Tags: Ambit, Teva, FDA clearance